What is Adaptive Biotechnologies?
Headquartered in Seattle, Adaptive Biotechnologies is a commercial-stage enterprise dedicated to transforming the diagnosis and treatment of complex diseases. Its core technology, the immunosequencing platform, integrates proprietary chemistry with advanced data analytics to generate clinical-grade immunomics data. Beyond research, the company provides the clonoSEQ diagnostic test, a vital tool for detecting and monitoring cancer cells in patients. Through strategic alliances with industry giants like Microsoft and Genentech, the company is actively bridging the gap between high-throughput sequencing and clinical application, positioning itself as a leader in the intersection of biotechnology and digital health.
How much funding has Adaptive Biotechnologies raised?
Adaptive Biotechnologies has raised a total of $1B across 10 funding rounds:
Series A
$5.8M
Series B
$2.6M
Series C
$5M
Series D
$100M
Series E
$94M
Series F
$195M
Corporate Investment
$45M
Stock Offering
$345M
Other Financing Round
$250M
Series A (2011): $5.8M, investors not publicly disclosed
Series B (2012): $2.6M, investors not publicly disclosed
Series C (2014): $5M featuring Viking Global Investors
Series D (2014): $100M backed by Viking Global Investors
Series E (2015): $94M with participation from Undisclosed
Series F (2015): $195M led by Tiger Management, Matrix Capital Management, Casdin Capital, Alexandria Real Estate Equities, Senator Investment Group, Rock Springs Capital, and Viking Global Investors
Corporate Investment (2017): $45M supported by Microsoft
Stock Issuance/Offering (2019): $345M featuring Undisclosed
Other Financing Round (2022): $250M backed by OrbiMed
Key Investors in Adaptive Biotechnologies
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
Microsoft
Microsoft Corp. is a global technology leader providing software, hardware, and cloud services, with a strategic interest in developing diagnostic tests for early disease detection.
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation cycles.
What's next for Adaptive Biotechnologies?
Looking ahead, Adaptive Biotechnologies is well-positioned to leverage its recent capital infusion to accelerate the commercialization of its diagnostic pipeline and deepen its collaborative research efforts. The focus remains on expanding the clinical utility of its immune medicine platform, particularly in early disease detection and the development of neoantigen-directed T cell therapies. As the company matures, its ability to integrate machine learning into clinical workflows will likely serve as a primary driver for long-term value creation, ensuring it remains at the forefront of the precision medicine revolution.
See full Adaptive Biotechnologies company page
